ALOPM.PA Oncodesign Precision Medicine

Healthcare Biotechnology Euronext Paris
0.2400 EUR
Close of Nov 5, 2026
0.2000 0.9200
Market cap
EUR 4.58M
P/E
-
P/B
1.17x
ROE
10.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALOPM.PA undervalued?

Graham number

The Graham number of Oncodesign Precision Medicine cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oncodesign Precision Medicine fundamental analysis

No fundamental analysis for Oncodesign Precision Medicine yet.

Oncodesign Precision Medicine stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oncodesign Precision Medicine

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced…

Full company profile